- Targeted stakeholdersFaster detection and tracking of emerging pathogens through real-time AI-enabled surveillance.
- Targeted stakeholdersAccelerated vaccine and therapeutic identification and development using AI-driven analysis.
- Targeted stakeholdersImproved national coordination and a system-of-systems approach across agencies and private partners.
MedShield Act of 2025
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The MedShield Act of 2025 requires HHS to implement a MedShield program using artificial intelligence for continuous pandemic preparedness and response.
The program will operationalize NSCAI recommendations, build AI-enabled pathogen surveillance, accelerate vaccine and therapeutic development, and coordinate across federal agencies and international partners.
HHS must produce a report within 180 days (unclassified with possible classified annex).
Moderate bipartisan appeal on preparedness and AI, but requires appropriations, faces privacy/oversight concerns and interagency coordination challenges.
Relative to its intended legislative type, this bill establishes and funds a new HHS program to operationalize AI for pandemic preparedness, with a clear high‑level purpose and initial congressional reporting, but relies on high‑level directives rather than detailed operational, governance, and safeguard provisions.
Left emphasizes equity, transparency, and public oversight needs
Who stands to gain, and who may push back.
- Targeted stakeholdersExpanded surveillance may raise privacy and civil liberties concerns about health and genomic data use.
- Federal agenciesConcentrating capabilities in a federal program could heighten cybersecurity risks and sensitive data exposure.
- Federal agenciesFederal centralization may alter state roles and public health authorities during response activities.
Why the argument around this bill splits.
Left emphasizes equity, transparency, and public oversight needs
Generally favorable to stronger federal public-health preparedness and use of technology to save lives.
Concerned the bill lacks explicit civil‑liberties, equity, pricing, and public‑oversight safeguards for AI and private sector partnerships.
Views the funding commitment as a useful start but wants conditions to ensure equitable access and transparency.
Supportive of investing in preparedness and practical use of AI, while cautious about costs, execution, and oversight.
Wants clear performance metrics, interagency roles, and safeguards for data sharing and international coordination.
Likely to back the bill if reporting, transparency, and accountability provisions are strengthened.
Mixed to skeptical: supports biodefense but wary of expanding federal power and spending.
Concerned about large appropriations, federal control over private sector innovation, and international data sharing obligations.
Prefers market-driven solutions, state flexibility, and tighter limits on centralized surveillance and classified authority without strong congressional control.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Moderate bipartisan appeal on preparedness and AI, but requires appropriations, faces privacy/oversight concerns and interagency coordination challenges.
- Whether appropriators will fund the authorized amounts
- Overlap and turf disputes with CDC, NIH, BARDA, DoD
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Left emphasizes equity, transparency, and public oversight needs
Moderate bipartisan appeal on preparedness and AI, but requires appropriations, faces privacy/oversight concerns and interagency coordinati…
Relative to its intended legislative type, this bill establishes and funds a new HHS program to operationalize AI for pandemic preparedness, with a clear high‑level purpose and initial congressional reporting, but relie…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.